TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01066559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High flux polymethylmetacrylate membrane
Description: Patients will be hemodialysed with high flux polymethylmetacrylate membranes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polysulfone membrane
Description: Patients be hemodialysed with polysulfone membranes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B serological control
Description: It will be assessed at week 16, week 20 and week 40

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B serological control
Description: It will be assessed at week 16, week 20 and week 40

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seric sCD40 level
Description: Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seric sCD40 level
Description: Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
Study: NCT01427712

Intervention type: DRUG
Intervention: Pancrelipase
Study: NCT02081651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parmigiano Reggiano cheese
Study: NCT00059475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycoprotein 100 (GP100): 209-217 (210M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: 720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51
Study: NCT03142893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin
Description: Gonadorelin IV injection is given twice per Inpatient Stay
Study: NCT01103401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine
Description: Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine
Description: Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
Study: NCT03633773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC-1 CART cell immunotherapy
Description: After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
Study: NCT03142893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin
Description: Gonadorelin IV injection is given twice per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin
Description: Gonadorelin IV injection is given twice per Inpatient Stay
Study: NCT00016835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-gingival scaling and placebo
Description: Included in arm/group description.
Study: NCT00059475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51
Study: NCT00016835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgingival scaling and metronidazole
Description: Included in arm/group description.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgingival scaling and doxycycline
Description: Included in arm/group description.
Study: NCT02803190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICG
Description: All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTG
Description: All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
Study: NCT03676673

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5

Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
Study: NCT03591107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTSD Care Management (PCM)
Description: Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Enhanced Usual Care (MEU)
Description: Education and feedback alone
Study: NCT00869141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)
Description: Subjects may receive glaucoma medications after Ahmed valve implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)
Description: Subjects may receive glaucoma medications after Ahmed valve implantation
Study: NCT00059475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melanoma antigen recognized by T-cells (MART)-1: 27-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melanoma antigen recognized by T-cells (MART)-1: 27-35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
Study: NCT02338362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate inhaler
Description: fluticasone propionate 250 µg metered-dose inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo inhaler
Description: saline metered dose inhaler
Study: NCT03330834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells to treat advanced lung cancer
Description: Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells.
Study: NCT03074006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: 50mg tablets (doses will be determined through dose-escalation part)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: 50mg tablets (doses will be determined through dose-escalation part)
Study: NCT00968617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578
Description: MK2578 1.0 mcg/kg/month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578
Description: MK2578 2.0 mcg/kg/month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2578
Description: MK2578 3.6 mcg/kg/month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: darbepoetin alfa
Description: darbepoetin alfa
Study: NCT04879472

Intervention type: PROCEDURE
Intervention: Osteosynthesis
Description: The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails

Intervention type: PROCEDURE
Intervention: Osteosynthesis
Description: The elderly are mainly treated by arthroplasty (total hip replacement or hemiarthroplasty) while the younger age groups, by osteosynthesis either using pins, screws or nails
Study: NCT01924936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Online Program
Description: DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: DBT Online Program
Description: DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Online Program
Description: DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
Study: NCT00306228

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postfibrinolysis percutaneous coronary intervention
Description: implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postfibrinolysis percutaneous coronary intervention
Description: implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
Study: NCT00812227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Psychotherapy
Description: Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
Study: NCT03142893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin
Description: Gonadorelin IV injection is given twice per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin
Description: Corticorelin IV injection is given twice per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin
Description: Corticorelin IV injection is given twice per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin
Description: Corticorelin IV injection is given twice per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin
Description: Corticorelin IV injection is given twice per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo for ketoconazole are given 4 times per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo for ketoconazole are given 4 times per Inpatient Stay
Study: NCT00306228

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postfibrinolysis percutaneous coronary intervention
Description: implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
Study: NCT03142893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution for Injection
Description: Saline Solution (placebo) for ganirelix subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution for Injection
Description: Saline Solution (placebo) for ganirelix subcutaneous injection
Study: NCT03322475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4 laser system
Description: The PiQo4 laser system
Study: NCT03944538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity
Description: The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
Study: NCT03479671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
Study: NCT03395873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: * Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days
Study: NCT02397226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High ligation/stripping
Study: NCT03944538

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Wellness
Description: The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
Study: NCT01612052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic Prophylaxis
Description: Comparing the antibiotic treatment related to surgery
Study: NCT02397226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vein stripping catheter
Study: NCT00752401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels \>2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
Study: NCT02221778

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:~Prescription dose(Gy) / (MLD) (Gy)~50 / 13~45 / 15~40 / 15~35 / 15.5~30 / 16~27.5 / 17~If the dose constraints cannot be met, prescription will be according to the level immediately bellow.~Treatment will be delivered in 5 fractions in consecutive working days
Study: NCT00108407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twelve Step Facilitation Therapy
Study: NCT01850888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131 I-Metaiodobenzylguanidine (131I-MIBG)
Description: Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
Study: NCT00717158

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Usual medical care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Case management
Description: Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
Study: NCT01850888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium iodide solution
Description: For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000).
Study: NCT04178018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoacoustic imaging
Description: -Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: -The ultrasound is being used in conjunction with the photoacoustic imaging
Study: NCT05171127

Intervention type: PROCEDURE
Intervention: Diffuse Reflectance Spectroscopy
Description: Measurements of DRS patterns in extirpated tumor and cerebral tissue
Study: NCT06537024

Intervention type: PROCEDURE
Intervention: RTSA
Study: NCT06541106

Intervention type: OTHER
Intervention: Multi-disciplinary assessment
Description: 1. Comprehensive evaluation was performed by multi-disciplinary experts to assess the prognosis of unruptured VBDAs and develop appropriate treatment strategies.~2. Preoperative cranial MRI, CTA, DSA and other imaging tests were used to determine the aneurysm site, morphology, size, presence of compression symptoms, and whether it was accompanied by an intramural hematoma.
Study: NCT01850888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell infusion
Description: The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum \> 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum \>2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
Study: NCT01973478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Study: NCT03412994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard second-line chemotherapy
Description: The second line standard chemotherapy regimen recommended by the NCCN

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard second-line chemotherapy
Description: The second line standard chemotherapy regimen recommended by the NCCN
Study: NCT00267579

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strongest Families (formerly Family Help Program): Behaviour Disorder Program
Description: Evidence-based psychological and behavioural Distance Intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families (formerly Family Help Program): Behaviour Disorder Program
Description: Evidence-based psychological and behavioural Distance Intervention
Study: NCT04196088

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultivision Artificial Intelligence Software
Description: Screening Colonoscopy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No Artificial Intelligence Software enhancement
Description: Screening Colonoscopy
Study: NCT02449967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）